Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3497134 | 0.81 | L3MBTL1 (1.00) | L3MBTL1KMT2AMEN1MGLLMAPT | |
| SCHEMBL3192173 | 0.79 | L3MBTL1 (0.54) | L3MBTL1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL3192184 | 0.79 | L3MBTL1 (0.54) | L3MBTL1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL3183055 | 0.79 | L3MBTL1 (0.53) | L3MBTL1MAPTLMNAALDH1A1 | |
| SCHEMBL3183041 | 0.79 | L3MBTL1 (0.53) | L3MBTL1MAPTLMNAALDH1A1 | |
| SCHEMBL3495027 | 0.77 | L3MBTL1 (0.67) | L3MBTL1KMT2AMEN1MGLLMAPT | |
| SCHEMBL15836588 | 0.76 | MEN1 (0.65) | L3MBTL1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL10038047 | 0.76 | MEN1 (0.65) | L3MBTL1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL3495788 | 0.76 | MEN1 (0.65) | L3MBTL1KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL3173943 | 0.75 | L3MBTL1 (0.60) | L3MBTL1KMT2AMEN1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137294-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | GENETIC TECHNOLOGIES LIMITED (AU) | 2010-06-03 | — | — | US | claimed |
| EP-2086534-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | Genetic Technologies Limited (AU) | 2009-08-12 | — | — | EP | claimed |
| WO-2008058342-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | GENETIC TECHNOLOGIES LIMITED (AU) | 2008-05-22 | — | — | WO | claimed |
| US-20100137294-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | GENETIC TECHNOLOGIES LIMITED (AU) | 2010-06-03 | — | — | US | disclosed |
| EP-2086534-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | Genetic Technologies Limited (AU) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008058342-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | GENETIC TECHNOLOGIES LIMITED (AU) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137294-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | PPP1R10, TASP1, PPP5C | L3MBTL1 598/4885KMT2A 1199/4885MEN1 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.